New $1.9M DoD-Funded Trial Aims to Improve Swallowing in Early Parkinson’s Patients

Swallowing problems, or dysphagia, affect up to 80% of people with Parkinson’s disease. These issues can lead to malnutrition, aspiration, recurrent lung infections, and a major decline in quality of life.

A new three-year, $1.9 million grant from the U.S. Department of Defense will support a phase 2 clinical trial designed to change that.

A Major New Study Led by UT Health San Antonio

Giselle Carnaby, PhD, MPH, a leading swallowing-disorders researcher at UT Health San Antonio, will oversee a multisite, randomized, double-blind trial to test an innovative therapy that retrains and strengthens swallowing in early Parkinson’s.

Key details:

• ~80 participants
• Ages 30 to 90
• Diagnosed with Parkinson’s
• Must be active-duty service members, veterans, or direct relatives

Carnaby says the trial fills a major gap:

“Swallowing disorders profoundly affect independence and health, yet treatment options remain limited.”

Why Parkinson’s Patients Struggle to Swallow

Parkinson’s disease disrupts the brain pathways that control movement, including the precise coordination needed for the nearly 30 muscles involved in swallowing.

Carnaby explains it as a signal problem:

“It’s like the brain’s radio is slightly off the station. Sometimes the signal comes through; other times it doesn’t. That inconsistency affects muscle timing.”

This breakdown can lead to:

• Delayed or slowed swallowing
• Food getting stuck
• Food or liquid entering the airway (aspiration)
• Persistent coughing and lung infections

The new therapy aims to strengthen the brain-muscle connection through structured, targeted swallowing exercises.

Pilot Study Results: Encouraging Early Gains

Carnaby’s team recently completed a pilot trial using an intensive swallowing-exercise program. Patients showed:

• Better swallowing performance
• Fewer choking or coughing episodes
• Higher confidence while eating

The improvements were significant enough to justify a larger, controlled trial.

Inside the New Study: Testing “SwallowFIT”

The full trial will compare:

• SwallowFIT – a proactive, high-intensity intervention
• Usual care

Participants will be followed at three and six months to assess:

• Swallowing function
• Aspiration rates
• Nutritional status
• Hospitalizations
• Biomechanical and imaging markers of swallowing efficiency

Where the Study Will Happen

• Brooke Army Medical Center, San Antonio – primary recruitment
• UT Health San Antonio – therapy delivery and data repository

The multidisciplinary team includes neurologists, biostatisticians, and military medical specialists.

What the SwallowFIT Program Involves

The therapy is rooted in neuroplasticity, the brain’s ability to rewire itself.

The structure:

• Two sessions per week for six weeks
• Guided by trained speech-language pathologists
• Combination of strength-building and coordination exercises
• Daily at-home practice

Carnaby notes:

“The exercises look simple, but they’re designed to recalibrate motor pathways. The goal is safer, more efficient swallowing.”

Why This Matters for Parkinson’s Patients

Better swallowing can:

• Reduce aspiration, a leading cause of death in Parkinson’s
• Improve nutrition and hydration
• Boost independence and social confidence
• Reduce hospitalizations

Carnaby highlights an often-overlooked benefit:

“Sharing a meal without fear of coughing or choking is incredibly powerful.”

Looking Ahead: A Path to Standard Care

If successful, this trial could pave the way for swallowing therapy to become a routine component of early Parkinson’s treatment. Future research may combine exercises with medications or neuromodulation to amplify results.

With Parkinson’s now the fastest-growing neurodegenerative disease, the impact could be national in scale.

As Carnaby puts it:

“This is about giving patients more time and a better quality of life. That’s what drives our work.”

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!